SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer, will participate in a panel discussion at the 2017 BIO International Convention being held June 19-22 in San Diego. The panel will focus on the increasing prevalence of fungal infections and antifungal resistance, and highlight the urgent needs and opportunities for new antifungal development.
Dr. Stein is also the chairman of the Antimicrobials Working Group (AWG), an industry-led coalition of emerging antimicrobial companies that aims to provide a collective voice in policy and regulatory solutions. He is widely considered one of the nation’s leading experts in the discovery and development of antimicrobials. Details of the panel discussion are as follows:
Session Title: Antifungus
Among Us: Recognizing Vulnerability and Opportunity with the
Next-Generation of Antifungals
Session ID: 22252
Date and time: Tuesday, June 20, 2017, at 4:15 p.m. PT
Location: San Diego Convention Center, Room 9, Upper Level
- Jeffrey Stein, Ph.D., president and chief executive officer, Cidara Therapeutics
- Tom Chiller, M.D., M.P.H., associate director for epidemiologic science, Centers for Disease Control and Prevention (CDC)
- Tim Cooke, Ph.D., chief executive officer, Novadigm Therapeutics
- Marco Taglietti, M.D., president and chief executive officer, Scynexis
- Robert Schotzinger, M.D., Ph.D., president and chief executive officer, Viamet Pharmaceuticals
About Fungal Infections
Approximately 97,000 Americans die from hospital-related fungal infections each year and 90 percent of these infections are caused by two common fungi, Candida and Aspergillus. The emergence of a new and virulent fungal infection called Candida auris is also a growing public health concern due its resistance to existing antifungal agents. As of May 2017, Candida auris has been identified in more than 120 patients in the United States and linked to four hospital deaths, according to the Centers for Disease Control and Prevention.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. CD101 IV is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara recently received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of CD201. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness, safety, and other attributes of CD101, including the potential for these compounds to successfully treat and prevent fungal infections and simplify prophylaxis compared to current antifungal agents. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-K most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.